An ongoing dialogue on HIV/AIDS, infectious diseases,
March 1st, 2009
Sedation for Colonoscopies in HIV Patients: Debate Rages
Here’s a problem we’re grappling with:
A patient with HIV needs a colonoscopy, but is on either a ritonavir-boosted protease inhibitor or an efavirenz-based regimen.
(This must be something like 90% of HIV patients as of March 1, 2009, based on my extremely unscientific gut impression.)
For efavirenz, midazolam is contraindicated; for ritonavir, same story — or “consider therapy modification”, according to one source I found. Ditto fentanyl.
So what should be given for sedation? (Important side note: if you told me pre-1996 that this would be a critical management question for my HIV patients, I would have thought you were out of your mind.)
Lots of different views here in Boston, including:
- Give the usual meds, titrate to effect
- NEVER give midazolam with either efavirenz or ritonavir; instead, use lorazepam, etc
- Stop HIV meds 1 day in advance, then give midazolam and fentanyl
Does anyone know? Or does anyone have sufficient experience to share?
Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: colonoscopy, fentanyl, HIV, hiv patients, lorazepam, midazolam, protease, protease inhibitor, titrate
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “Sedation for Colonoscopies in HIV Patients: Debate Rages”
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Why We Have Antibiotic Shortages and Price Hikes — And What One Very Enterprising Doctor Did in Response
- Brave New Name — How PCP Became PJP and Why It Matters
- The Riveting Conclusion of How PCP Became PJP
- How Electronic Health Records Tyrannize Doctors — ID Doctors in Particular
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- Rising Rates of Perinatal HIV: Maryland, 2022
- Do Children Need a Booster of Typhoid Conjugate Vaccine?
- Infection with Tecovirimat-Resistant Mpox Virus Is on the Rise in the U.S.
- Kidney Transplantation: Offering HOPE for Those with HIV
- Observations from ID and Beyond: Brave New Name — How PCP Became PJP and Why It Matters
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
I would titrate to effect. After all, we use fentanyl patches in patients on efavirenz. You just start at a lower dose.
Paul, I would sedate as usual as it has been my experience (hundreds of cases of endoscopy in patients on these meds) that there are no significant adverse effects, and there are no cases of clinically relevant drug interactions using fentanyl/midazolam for conscious sedation in patients on these agents (thousands of cases). Until it is a clinical relevant interaction (vs pharmacological or theoretical effect as it is at this time), deviating from a safe and time-tested sedation strategy for endoscopy does not seem justified.
Brian, many thanks for your input — will share with our colleagues.
Paul
[…] HIV-Infected Endoscopy Patients Posted by M. Brian Fennerty on March 14th, 2009 In a recent blog post, ID expert Paul Sax raised the question of which sedatives should be used when scoping HIV-infected […]